Ringborg, U. et al. The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of radiotherapy for cancer including a prospective survey of radiotherapy practice in Sweden 2001 – Summary and conclusions. Acta Oncol. 42, 357–365 (2003).
Mackie, T. R. et al. Image guidance for precise conformal radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 56, 89–105 (2003).
Li, G. et al. Advances in 4D medical imaging and 4D radiation therapy. Technol. Cancer Res. Treat. 7, 67–81 (2008).
Otto, K. Volumetric modulated arc therapy: IMRT in a single gantry arc. Med. Phys. 35, 310–317 (2008).
Teoh, M., Clark, C. H., Wood, K., Whitaker, S. & Nisbet, A. Volumetric modulated arc therapy: a review of current literature and clinical use in practice. Br. J. Radiol. 84, 967–996 (2011).
Yu, C. X. Intensity-modulated arc therapy with dynamic multileaf collimation: an alternative to tomotherapy. Phys. Med. Biol. 40, 1435–1449 (1995).
Rivera, A. L. et al. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol. 12, 116–121 (2010).
Rouzier, R. et al. Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses. Breast Cancer Res. Treat. 139, 621–637 (2013).
Redza-Dutordoir, M. & Averill-Bates, D. A. Activation of apoptosis signalling pathways by reactive oxygen species. Biochim. Biophys. Acta Mol. Cell Res. 1863, 2977–2992 (2016).
Maier, P., Hartmann, L., Wenz, F. & Herskind, C. Cellular pathways in response to ionizing radiation and their targetability for tumor radiosensitization. Int. J. Mol. Sci. 17, 102 (2016).
Ouellette, M. M., Zhou, S. & Yan, Y. Cell signaling pathways that promote radioresistance of cancer cells. Diagnostics 12, 656 (2022).
Barker, H. E., Paget, J. T. E., Khan, A. A. & Harrington, K. J. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat. Rev. Cancer 15, 409–425 (2015).
Kumari, S. et al. Immunomodulatory effects of radiotherapy. Int. J. Mol. Sci. 21, 8151 (2020).
Ghasemi, Z. et al. Fractionated radiation promotes proliferation and radioresistance in bystander A549 cells but not in bystander HT29 cells. Life Sci. 257, 118087 (2020).
Chalmers, A. J. & Carruthers, R. D. Radiobiology summaries: DNA damage and repair. Clin. Oncol. 33, 275–278 (2021).
Feng, W., Smith, C. M., Simpson, D. A. & Gupta, G. P. Targeting non-homologous and alternative end joining repair to enhance cancer radiosensitivity. Semin. Radiat. Oncol. 32, 29–41 (2022).
Chang, H. H. Y., Pannunzio, N. R., Adachi, N. & Lieber, M. R. Non-homologous DNA end joining and alternative pathways to double-strand break repair. Nat. Rev. Mol. Cell Biol. 18, 495–506 (2017).
Wyatt, D. W. et al. Essential roles for polymerase θ-mediated end joining in the repair of chromosome breaks. Mol. Cell 63, 662–673 (2016).
Li, X. & Heyer, W. D. Homologous recombination in DNA repair and DNA damage tolerance. Cell Res. 18, 99–113 (2008).
Weber, A. M. & Ryan, A. J. ATM and ATR as therapeutic targets in cancer. Pharmacol. Ther. 149, 124–138 (2015).
Aubrey, B. J., Kelly, G. L., Janic, A., Herold, M. J. & Strasser, A. How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression. Cell Death Differ. 25, 104–113 (2018).
Engeland, K. Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM. Cell Death Differ. 25, 114–132 (2018).
Baumann, M. et al. EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother. Oncol. 83, 238–248 (2007).
Thiruthaneeswaran, N. et al. Lost in application: measuring hypoxia for radiotherapy optimisation. Eur. J. Cancer 148, 260–276 (2021).
West, C. M. & Slevin, F. Tumour hypoxia. Clin. Oncol. 31, 595–599 (2019).
Wouters, B. G. & Koritzinsky, M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat. Rev. Cancer 8, 851–864 (2008).
Bolland, H., Ma, T. S., Ramlee, S., Ramadan, K. & Hammond, E. M. Links between the unfolded protein response and the DNA damage response in hypoxia: a systematic review. Biochem. Soc. Trans. 49, 1251–1263 (2021).
Yaromina, A. et al. Radiobiological hypoxia, histological parameters of tumour microenvironment and local tumour control after fractionated irradiation. Radiother. Oncol. 96, 116–122 (2010).
Tang, M., Bolderson, E., O’Byrne, K. J. & Richard, D. J. Tumor hypoxia drives genomic instability. Front. Cell Dev. Biol. 9, 626229 (2021).
Semenza, G. L. Heritable disorders of oxygen sensing. Am. J. Med. Genet. A 185, 3334–3339 (2021).
Semenza, G. L. The genomics and genetics of oxygen homeostasis. Annu. Rev. Genomics Hum. Genet. 21, 183–206. (2020).
Vadysirisack, D. & Ellisen, L. W. mTOR activity under hypoxia. Methods Mol. Biol. 821, 44–58 (2012).
Liu, K. X., Everdell, E., Pal, S., Haas-Kogan, D. A. & Milligan, M. G. Harnessing lactate metabolism for radiosensitization. Front. Oncol. 11, 672339 (2021).
Peitzsch, C., Kurth, I., Ebert, N., Dubrovska, A. & Baumann, M. Cancer stem cells in radiation response: current views and future perspectives in radiation oncology. Int. J. Radiat. Biol. 95, 900–911 (2019).
Linge, A. et al. HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: a multicentre retrospective study of the German Cancer Consortium Radiation. Radiother. Oncol. 121, 364–373 (2016).
Vlashi, E. & Pajonk, F. Cancer stem cells, cancer cell plasticity and radiation therapy. Semin. Cancer Biol. 31, 28–35 (2015).
Lee, S. Y. et al. Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation. Mol. Cancer 16, 10 (2017).
Quail, D. F., Taylor, M. J. & Postovit, L. M. Microenvironmental regulation of cancer stem cell phenotypes. Curr. Stem Cell Res. Ther. 7, 197–216 (2012).
Diehn, M. et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458, 780–783 (2009).
Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756–760 (2006).
Peitzsch, C., Kurth, I., Kunz-Schughart, L., Baumann, M. & Dubrovska, A. Discovery of the cancer stem cell related determinants of radioresistance. Radiother. Oncol. 108, 378–387 (2013).
Zhong, J. T. et al. GLUT-1 siRNA enhances radiosensitization of laryngeal cancer stem cells via enhanced DNA damage, cell cycle redistribution, and promotion of apoptosis in vitro and in vivo. Onco Targets Ther. 12, 9129–9142 (2019).
Kaseb, H. O., Fohrer-Ting, H. F., Lewis, D. W., Lagasse, E. & Gollin, S. Identification, expansion and characterization of cancer cells with stem cell properties from head and neck squamous cell carcinomas. Exp. Cell Res. 348, 75–86 (2016).
Emami Nejad, A. et al. The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell Int. 21, 1–26 (2021).
Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31–46 (2022).
Kachikwu, E. L. et al. Radiation enhances regulatory T cell representation. Int. J. Radiat. Oncol. Biol. Phys. 81, 1128–1135 (2011).
Honeychurch, J. & Illidge, T. M. The influence of radiation in the context of developing combination immunotherapies in cancer. Ther. Adv. Vaccines Immunother. 5, 115–122 (2017).
留言 (0)